We are live on ! Find out more
CSS

Cubist Systematic Strategies Portfolio holdings

AUM $21B
1-Year Est. Return 21.48%
This Fund
S&P 500
This Quarter Est. Return
-4.64%
1 Year Est. Return
+21.48%
3 Year Est. Return
+78.34%
5 Year Est. Return
+110.56%
10 Year Est. Return
+239.04%
AUM
$11.8B
AUM Growth
+$1.34B
Cap. Flow
+$2.18B
Cap. Flow %
18.39%
Top 10 Hldgs %
3.51%
Holding
4,052
New
613
Increased
1,643
Reduced
1,246
Closed
518

Top Buys

Rank Stock Value
1
ABT icon
Abbott
ABT
+$34.6M
2
WDAY icon
Workday
WDAY
+$33.5M
3
FRC
First Republic Bank
FRC
+$31.8M
4
ZTS icon
Zoetis
ZTS
+$31.3M
5
SYF icon
Synchrony
SYF
+$31M

Top Sells

Rank Stock Value
1
MDT icon
Medtronic
MDT
+$35.7M
2
HON icon
Honeywell
HON
+$31.7M
3
IP icon
International Paper
IP
+$30.5M
4
ADM icon
Archer Daniels Midland
ADM
+$23.8M
5
EMR icon
Emerson Electric
EMR
+$22.5M

Sector Composition

Rank Sector Weight
1 Technology 18.12%
2 Financials 17.75%
3 Healthcare 12.17%
4 Consumer Discretionary 11.8%
5 Industrials 11.52%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
BRZE icon
3501
Braze
BRZE
$3.24B
$8K ﹤0.01%
+200
New +$10K
IOT icon
3502
Samsara
IOT
$23.2B
$8K ﹤0.01%
509
-6,415
-93% -$122K
EPZM
3503
DELISTED
Epizyme, Inc
EPZM
$8K ﹤0.01%
7,200
-182,787
-96% -$298K
VIGL
3504
DELISTED
Vigil Neuroscience
VIGL
$7K ﹤0.01%
+1,000
New +$13.2K
APTX
3505
DELISTED
Aptinyx Inc. Common Stock
APTX
$6K ﹤0.01%
2,700
-223
-8% -$668
ANAB icon
3506
AnaptysBio
ANAB
$1.64B
$5K ﹤0.01%
213
-13,505
-98% -$409K
CLYM
3507
Climb Bio
CLYM
$778M
$5K ﹤0.01%
+638
New +$5.95K
NBSE
3508
DELISTED
NeuBase Therapeutics, Inc. Common Stock
NBSE
$5K ﹤0.01%
126
-190
-60% -$6.57K
IQ icon
3509
iQIYI
IQ
$1.31B
$4K ﹤0.01%
871
-45,469
-98% -$190K
TERN
3510
DELISTED
Terns Pharmaceuticals
TERN
$4K ﹤0.01%
+1,200
New +$5.12K
AVTX icon
3511
Avalo Therapeutics
AVTX
$1.06B
$3K ﹤0.01%
+1
New +$2.51K
LICY
3512
DELISTED
Li-Cycle Holdings Corp.
LICY
$3K ﹤0.01%
50
-5,409
-99% -$344K
AFMD
3513
DELISTED
Affimed
AFMD
$2K ﹤0.01%
44
– –
KRYS icon
3514
Krystal Biotech
KRYS
$9.81B
$2K ﹤0.01%
37
-4,477
-99% -$279K
LDTC
3515
DELISTED
LeddarTech
LDTC
$2K ﹤0.01%
+400
New +$1.95K
VRSK icon
3516
Verisk Analytics
VRSK
$23.6B
$2K ﹤0.01%
7
-24,687
-100% -$4.87M
XFOR icon
3517
X4 Pharmaceuticals
XFOR
$421M
$2K ﹤0.01%
+47
New +$2.69K
ACHL
3518
DELISTED
Achilles Therapeutics
ACHL
$2K ﹤0.01%
585
-425
-42% -$1.51K
MACK
3519
DELISTED
Merrimack Pharmaceuticals, Inc.
MACK
$2K ﹤0.01%
+368
New +$2.07K
COGT icon
3520
Cogent Biosciences
COGT
$7.1B
$1K ﹤0.01%
+90
New +$627
COOK icon
3521
Traeger
COOK
$172M
$1K ﹤0.01%
+2
New +$953
HTPA
3522
DELISTED
Highland Transcend Partners I Corp.
HTPA
$1K ﹤0.01%
100
– –
GNCA
3523
DELISTED
Genocea Biosciences, Inc.
GNCA
$1K ﹤0.01%
+900
New +$980
AAT
3524
American Assets Trust
AAT
$1.38B
– –
-15,530
Closed -$583K
ACIU icon
3525
AC Immune
ACIU
$232M
– –
-15,327
Closed -$76K
139 140
141
142 143

Similar funds

GIM
Glenmede Investment Management Philadelphia, Pennsylvania $20.7B AUM
ECM
Eisler Capital Management London, United Kingdom $22.6B AUM 9.36% 1-Year Est. Return
JFL
Jarislowsky, Fraser Ltd Montreal, Quebec, Canada $18.2B AUM 22.04% 1-Year Est. Return
BAM
Burgundy Asset Management Toronto, Ontario, Canada $10.6B AUM 13.39% 1-Year Est. Return
SF
Synovus Financial Columbus, Georgia $8.74B AUM 12.78% 1-Year Est. Return
WIM
Waverton Investment Management London, United Kingdom $7.77B AUM 25.07% 1-Year Est. Return
AIM
AXA Investment Managers Puteaux, France $37.1B AUM
SIG
Stonegate Investment Group Birmingham, Alabama $4.31B AUM 18.07% 1-Year Est. Return

Cubist Systematic Strategies's Q1 2022 Portfolio in Review

As of Q1 2022, Cubist Systematic Strategies held 4,052 positions worth $11.8B, up 13% from $10.5B the previous quarter. Its ten largest holdings account for 3.5% of the portfolio.

Cubist Systematic Strategies deployed $2.18B of net new capital in Q1 2022, opening 613 new positions and adding to 1,643 existing holdings. Its largest new stake was Trine II Acquisition Corp.: 2,018,590 shares worth $20.1M.

By sector, the portfolio is most concentrated in Technology at 18% of assets, down from 19% a quarter earlier, followed by Financials and Healthcare.

On the sell side, the largest reduction was Medtronic, an estimated $35.7M trimmed.

  • Cubist Systematic Strategies's largest Q1 2022 buy was Trine II Acquisition Corp.: 2,018,590 shares worth $20.1M.
  • Cubist Systematic Strategies added most to Abbott in Q1 2022, an estimated $34.6M increase.
  • Cubist Systematic Strategies's biggest Q1 2022 reduction was Medtronic, cutting an estimated $35.7M.
  • Cubist Systematic Strategies fully exited Trine II Acquisition Corp. Units, each consisting of one Class A Ordinary Share and one-half of one redeemable warrant in Q1 2022, selling an estimated $20.6M.
  • Cubist Systematic Strategies's ten largest holdings make up 3.5% of its $11.8B portfolio in Q1 2022.
  • Cubist Systematic Strategies opened 613 new positions and closed 518 in Q1 2022.
  • Cubist Systematic Strategies's portfolio value rose 13% quarter-over-quarter to $11.8B.

Based on Cubist Systematic Strategies's 13F filing for Q1 2022, filed 16 May 2022.